Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase-III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Next Previous
X
Search
Trial Profile

Phase-III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Anastrozole; Exemestane; Goserelin; Goserelin; Letrozole; Leuprorelin; Leuprorelin; Tamoxifen
  • Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Dec 2022 Results (n=1792) assessing the efficacy of everolimus in combination with ET in the adjuvant settingamong patients with high-risk hormone receptor-positive, HER2-negative BC presented at the 45th Annual San Antonio Breast Cancer Symposium
    • 20 Jun 2019 Status changed from recruiting to active, no longer recruiting.
    • 26 Jan 2016 Planned number of patients changed from 3500 to 1900, according to ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top